Daxor Announces BVA-100 Blood Volume Analyzer Purchase Agreements From Geisinger Medical Center of Danville, PA and University of Medicine and Dentistry of Newark, NJ

NEW YORK, NY--(Marketwire - June 29, 2007) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced purchase agreements from the Geisinger Medical Center of Danville, Pennsylvania and the University of Medicine and Dentistry of Newark, New Jersey (UMDNJ).

Geisinger Medical Center, recently named one of the Top 100 Hospitals in the country by Solucient's Center for Healthcare Improvement, is a 437-bed facility and the center of a physician-led health care system dedicated to health care, education, research and service spanning 40 counties and serving 2.5 million people. UMDNJ's University Hospital is the center of referral for many of New Jersey's most advanced medical services and specialty care programs. UMDNJ's commitment to education, primary care and specialized referral services has produced the most extensive array of inpatient and outpatient services available in the state of New Jersey.

Daxor's Blood Volume Analyzers, located within the respective nuclear medicine departments of these highly regarded hospitals, were purchased following the completion of a trial agreement to assess the benefit provided by the BVA-100 to diagnose patient blood volume derangements in various medical conditions and disease states. There is an increasing awareness by medical institutions that providing a measured blood volume provides additional clinical benefit to patients and a source for additional service referrals. Patients with a volume derangement who are treated without the benefit of a blood volume measurement are currently treated based upon clinical estimates.

Published medical articles, abstracts and clinical presentations continue to demonstrate that patients in various disease states benefit from the diagnostic information of a measured blood volume analysis. Daxor's Blood Volume Analyzer BVA-100 is the only FDA approved diagnostic device which provides for a 98% accurate measurement of blood volume.

Other nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer after using it on a clinical trial basis are The Mayo Clinic, The Cleveland Clinic, and New York University Medical Center. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 or Diane Meegan Investor Relations 212-330-8512